Aristotle Atlantic Partners’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $337K | Hold |
600
| – | – | 0.02% | 111 |
|
|
2025
Q4 | $406K | Hold |
600
| – | – | 0.02% | 86 |
|
|
2025
Q3 | $383K | Hold |
600
| – | – | 0.01% | 83 |
|
|
2025
Q2 | $322K | Hold |
600
| – | – | 0.01% | 83 |
|
|
2025
Q1 | $252K | Sell |
600
-10,112
| -94% | -$4.39M | 0.01% | 84 |
|
|
2024
Q4 | $4.43M | Sell |
10,712
-2,000
| -16% | -$877K | 0.14% | 71 |
|
|
2024
Q3 | $6.42M | Sell |
12,712
-30,194
| -70% | -$14.7M | 0.2% | 70 |
|
|
2024
Q2 | $20.9M | Sell |
42,906
-160
| -0.4% | -$80.3K | 0.68% | 42 |
|
|
2024
Q1 | $23.3M | Sell |
43,066
-337
| -0.8% | -$184K | 0.76% | 41 |
|
|
2023
Q4 | $24.1M | Buy |
43,403
+269
| +0.6% | +$126K | 0.85% | 40 |
|
|
2023
Q3 | $18.9M | Sell |
43,134
-180
| -0.4% | -$89.8K | 0.76% | 44 |
|
|
2023
Q2 | $21.8M | Buy |
43,314
+5,505
| +15% | +$2.64M | 0.82% | 42 |
|
|
2023
Q1 | $18.9M | Sell |
37,809
-7,979
| -17% | -$3.82M | 0.97% | 39 |
|
|
2022
Q4 | $18.7M | Sell |
45,788
-2
| -0% | -$776 | 1.05% | 34 |
|
|
2022
Q3 | $14.9M | Buy |
45,790
+161
| +0.4% | +$59.1K | 0.91% | 38 |
|
|
2022
Q2 | $16M | Buy |
45,629
+389
| +0.9% | +$159K | 1.23% | 24 |
|
|
2022
Q1 | $24.7M | Buy |
45,240
+87
| +0.2% | +$45.8K | 1.53% | 21 |
|
|
2021
Q4 | $29.7M | Buy |
45,153
+879
| +2% | +$552K | 1.73% | 20 |
|
|
2021
Q3 | $27.5M | Sell |
44,274
-8,593
| -16% | -$5.77M | 1.82% | 18 |
|
|
2021
Q2 | $33.4M | Buy |
52,867
+25
| +0% | +$13.8K | 2.2% | 11 |
|
|
2021
Q1 | $25.9M | Sell |
52,842
-3,693
| -7% | -$1.85M | 1.89% | 20 |
|
|
2020
Q4 | $28.3M | Sell |
56,535
-11,153
| -16% | -$4.99M | 2.18% | 14 |
|
|
2020
Q3 | $26.6M | Buy |
67,688
+32
| +0% | +$11.8K | 2.34% | 13 |
|
|
2020
Q2 | $22.3M | Buy |
67,656
+13,281
| +24% | +$3.85M | 2.15% | 17 |
|
|
2020
Q1 | $13.2M | Buy |
54,375
+44
| +0.1% | +$11.5K | 2.01% | 18 |
|
|
2019
Q4 | $14.2M | Buy |
54,331
+37,696
| +227% | +$9.93M | 1.81% | 23 |
|
|
2019
Q3 | $4.52M | Buy |
16,635
+47
| +0.3% | +$13.1K | 1.3% | 18 |
|
|
2019
Q2 | $4.57M | Buy |
16,588
+3
| +0% | +$739 | 1.33% | 18 |
|
|
2019
Q1 | $3.71M | Buy |
16,585
+2,998
| +22% | +$619K | 1.13% | 19 |
|
|
2018
Q4 | $2.53M | Buy |
13,587
+1,487
| +12% | +$305K | 0.89% | 23 |
|
|
2018
Q3 | $1.5M | Sell |
12,100
-1,426
| -11% | -$346K | 0.92% | 28 |
|
|
2018
Q2 | $2.95M | Hold |
13,526
| – | – | 1.02% | 24 |
|
|
2018
Q1 | $2.59M | Buy |
13,526
+3,067
| +29% | +$566K | 0.93% | 25 |
|
|
2017
Q4 | $1.64M | Buy |
+10,459
| New | +$1.65M | 0.59% | 31 |
|
Other funds holding IDXX
VCM
VPM
Aristotle Atlantic Partners's IDXX Position: Q1 2026 in Review
Aristotle Atlantic Partners held its Idexx Laboratories (IDXX) position steady in Q1 2026 at 600 shares worth $337K. The position accounts for 0.02% of the portfolio, ranked #111.
Aristotle Atlantic Partners first reported a position in IDXX in Q4 2017 and has held it in 34 quarters since. The position peaked at $33.4M in Q2 2021. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Aristotle Atlantic Partners held 600 shares of Idexx Laboratories worth $337K as of Q1 2026.
- Aristotle Atlantic Partners left its Idexx Laboratories share count unchanged in Q1 2026.
- Idexx Laboratories made up 0.02% of Aristotle Atlantic Partners's portfolio in Q1 2026, its #111 holding.
- Aristotle Atlantic Partners first reported a position in Idexx Laboratories in Q4 2017 and has held it in 34 quarters since.
- Aristotle Atlantic Partners's Idexx Laboratories position peaked at $33.4M in Q2 2021.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Aristotle Atlantic Partners's 13F filing for Q1 2026, filed 15 May 2026.